3-MeO-PCP: Difference between revisions
No edit summary |
Link addition and some clarification in relation to ACMD (I had no idea what that was and had to find the links, so, presumably the same holds true for others) |
||
| Line 39: | Line 39: | ||
3-MeO-PCP has a K{{sub|i}} of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma{{sub|1}} receptor<ref name='ACMD MXE report'>{{ cite web | url = http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012 | title = (ACMD) Methoxetamine Report (2012) | accessdate = 2012-10-22 | date = 2012-10-18 | format = PDF | pages = 14 | work = UK Home Office}}</ref> |
3-MeO-PCP has a K{{sub|i}} of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma{{sub|1}} receptor<ref name='ACMD MXE report'>{{ cite web | url = http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012 | title = (ACMD) Methoxetamine Report (2012) | accessdate = 2012-10-22 | date = 2012-10-18 | format = PDF | pages = 14 | work = UK Home Office}}</ref> |
||
On October 18, 2012 the |
On October 18, 2012 the [[Advisory Council on the Misuse of Drugs]] in the [[United Kingdom]] released a [http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012 report] about [[methoxetamine]], saying that the "harms of methoxetamine are commensurate with [[Class B drug|Class B]] of the [[Misuse of Drugs Act of 1971|Misuse of Drugs Act (1971)]]", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.<ref name='ACMD MXE report' /> |
||
==See also== |
==See also== |
||
Revision as of 12:17, 1 June 2014
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H27NO |
| Molar mass | 273.412 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug with hallucinogenic and sedative effects that has been sold as a research chemical. It is around the same potency as phencyclidine, but has slightly different effects due to its altered binding profile at various targets, particularly being somewhat more potent as an NMDA antagonist while having around the same potency as a dopamine reuptake inhibitor.[1][2][3][4]
The corresponding 4-methoxy derivative 4-MeO-PCP is also known, but is around 10 times less potent by weight than the 3-methoxy isomer, making it around the same potency as ketamine.
3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C [5]
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor[6]
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.[6]
See also
References
- ^ Vignon J, Vincent JP, Bidard JN, Kamenka JM, Geneste P, Monier S, Lazdunski M (July 1982). "Biochemical properties of the brain phencyclidine receptor". European Journal of Pharmacology. 81 (4): 531–42. doi:10.1016/0014-2999(82)90342-9. PMID 6214413.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Manallack DT, Wong MG, Costa M, Andrews PR, Beart PM (December 1988). "Receptor site topographies for phencyclidine-like and sigma drugs: predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses". Molecular Pharmacology. 34 (6): 863–79. PMID 2849051.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R (March 1989). "Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs". Pharmacology, Biochemistry, and Behavior. 32 (3): 699–705. doi:10.1016/0091-3057(89)90020-8. PMID 2544905.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Manallack DT, Davies JW, Beart PM, Saunders MR, Livingstone DJ (October 1993). "Analysis of the biological and molecular properties of phencyclidine-like compounds by chemometrics". Arzneimittel-Forschung. 43 (10): 1029–32. PMID 8267664.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Wallach J, De Paoli G, Adejare A, Brandt S (2013). "Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues". Drug Testing and Analysis.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ a b "(ACMD) Methoxetamine Report (2012)" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2012-10-22.
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |